Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+ HER2 Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Testing effectiveness (Phase 2)UnknownNCT03906669
What this trial is testing

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Tumor
St Vincent's Hospital 200
Large-scale testing (Phase 3)Ended earlyNCT00543127
What this trial is testing

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 870
Testing effectiveness (Phase 2)Active Not RecruitingNCT05101096
What this trial is testing

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Triple-Negative Breast CancerHR+/HER2- Metastatic Breast Cancer+1 more
Gilead Sciences 135
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07333937
What this trial is testing

Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer

Who this might be right for
Brest Cancer
Xijing Hospital 35
Large-scale testing (Phase 3)Study completedNCT02511639
What this trial is testing

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer Metastatic
Istituto Oncologico Veneto IRCCS 110
Not applicableUnknownNCT06344780
What this trial is testing

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 200
Not applicableLooking for participantsNCT06185569
What this trial is testing

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon 4,500
Not applicableStudy completedNCT07086196
What this trial is testing

Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 350
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)Study completedNCT03222856
What this trial is testing

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Who this might be right for
Breast Cancer
MedSIR 44
Not applicableStudy completedNCT04943497
What this trial is testing

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,390
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Testing effectiveness (Phase 2)Looking for participantsNCT06611813
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Looking for participantsNCT07198724
What this trial is testing

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more
Kristina A. Fanucci 65
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07441486
What this trial is testing

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 50
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07254858
What this trial is testing

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Wenzhou Medical University 302
Testing effectiveness (Phase 2)Looking for participantsNCT06374459
What this trial is testing

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Who this might be right for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine 152
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06680596
What this trial is testing

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Who this might be right for
Breast Cancer MetastaticBreast Cancer Stage IV
UNICANCER 80
Next Page